Cilengitide in Treating Children With Refractory Primary Brain Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of cilengitide in treating
children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow
the growth of brain cancer cells by stopping blood flow to the tumor.